Product Images Rivastigmine Transdermal System
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 18 images provide visual information about the product associated with Rivastigmine Transdermal System NDC 63629-2066 by Bryant Ranch Prepack, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Label - lbl636292066
This is a description of a pharmaceutical product called NILD. It is a rivastigmine transdermal system that is used for transdermal use only. The system contains 18mg rivastigmine, providing 9.5mg rivastigmine every 24 hours. The patch should be worn for 24 hours and shouldn't be cut. It should be applied immediately to an intact skin after removal from the pouch and the location of each new patch should be changed. The patch should be stored at 25°C (77°F) with excursions permitted to 15° to 30°C (59° to 86°F). This product is available in one unit with an NDC number of 63629-2066-1 and is only for Rx use.*
Chemical Structure - rivastigmine 01
Figure 1 - rivastigmine 02
Figure 2 - rivastigmine 03
This is a table providing the concentration of Rivastigmine in ng/mL, under different dosages (13.3 mg/24 hours, 9.5 mg/24 hours, 4.6mg/24 hours) and different number of patients (n=19, n=22, n=22).*
Figure 3 - rivastigmine 04
Figure 4 - rivastigmine 05
Figure 5 - rivastigmine 06
Figure 6 - rivastigmine 07
Figure 7 - rivastigmine 08
This appears to be a statistical analysis of the improvement observed in patients receiving Rivastigmine Transdermal System over a period of 8, 16, and 24 weeks of treatment. The analysis compares mean difference and standard errors of the LS means in patients receiving a 5 cm patch versus a 15 cm patch. The results indicate that patients receiving the larger patch showed a significant improvement compared to those who received the smaller patch.*
Figure 8 - rivastigmine 09
This is a clinical study evaluating the efficacy of Rivastigmine Transdermal System in improving cognitive decline over a period of 16 weeks. The study compares two dosages of the system (15 cm² and 5 cm²) and reports least squares means (LS means) and standard errors of the LS means (STE) obtained through an analysis of covariance model adjusted for pooled center and baseline. The statistical significance at a level of 0.05 is also reported.*
Figure A - rivastigmine 10
Figure B - rivastigmine 11
This is a list of body parts where Lenge, Z and Lk have been mentioned along with Left or Right Upper Arm, Left or Right Side of Chest, Left or Right Upper Back and Left or Right Lower Back. It is unclear what Lenge, Z and Lk indicate as the text appears to be incomplete.*
Figure C - rivastigmine 12
Figure D - rivastigmine 13
Figure E - rivastigmine 14
Figure F - rivastigmine 15
Figure G - rivastigmine 16
Figure H - rivastigmine 17
The text appears to be a set of instructions for disposing of a slide folded patch. The patch should be placed in the trash and the sticky sides should be folded together and placed in an empty pouch that has been saved. It also advises to keep the pouch away from children and pets.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.